• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in
Clinical Trials

Bavarian Nordic initiates Phase 2 trial

Malin Otmani

-

March 27, 2018

Share article on X
Share article on Linkedin


Published: March 27, 2018

Top stories

Profiles in Science – April 22, 2026

Julia Ravanis: Shining a light on knowledge

It’s one thing to “do” physics – but it’s another to explain its fundamentals to others, and the role that physics and other sciences play in their lives.

Sweden – April 21, 2026

Stable Swedish health exports despite an uncertain surrounding world

This is according to Swecare’s Health Export Barometer 2026 launched today, April 21.

Business Award – April 21, 2026

The winners at Swecare Export Award 2026

Encare will be awarded the Swecare Export Award 2026 and Bioservo will be named a Rising Star.

CDMO – April 21, 2026

Nanologica receives SEK 2 million order from customer in India

Nanologica has received an order of appx. SEK 2 million for the company’s silica-based purification media NLAB Saga.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

Clinical Trials - April 21, 2026

Novo Nordisk’s etavopivat met both co-primary endpoints in phase 3 trial

The company has announced the topline results from HIBISCUS, a phase 3 trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD).

Clinical Trials - April 19, 2026

Evaxion’s AI-Immunology platform demonstrates 86% vaccine target precision

Evaxion has announced new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets.

Clinical Trials - April 15, 2026

Promising results about new Lyme disease vaccine candidate

Pfizer and Valneva's Lyme disease vaccine candidate demonstrated strong efficacy in their Phase 3 VALOR trial.

Clinical Trials - April 13, 2026

Mendus starts clinical program in chronic myeloid leukemia

The company has completed preparations and received all regulatory approvals for the VITAL-CML trial.

Clinical Trials - April 13, 2026

Diamyd Medical discontinues Phase 3 trial and initiates strategic review

Diamyd Medical has announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes.

Clinical Trials - April 1, 2026

Cereno Scientific reports 12-month data

The company has announced initial learnings from the 12-month Expanded Access Program (EAP) with its lead drug candidate CS1 in pulmonary arterial hypertension (PAH).

Clinical Trials - March 31, 2026

Affibody reports positive Phase 3 data

The company has announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa (HS).

Sign up to our Newsletter!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.